Generation of iPSCs for Rare Diseases
Generation of induced pluripotent stem cell lines AKOSi002-A and AKOSi003-A from symptomatic female adults with Wilson disease
Induced pluripotent stem cells (iPSCs) represent excellent in vitro models to study rare diseases and perform high-throughput drug screening. CENTOGENE has established iPSC technology for rare monogenetic diseases in its Rostock headquarters based on patient-derived fibroblasts. Further advancements in this process is an ambitious task, which will be facilitated by close collaboration with local and global academic partners, as exemplified in a recent paper published in Stem Cell Research.